2-吡啶甲醇盐酸盐 | 6329-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-吡啶甲醇盐酸盐
• 英文名称: 2-pyridylcarbinol hydrochloride
• 英文别名: 2-pyridinemethanol hydrochloride；2-(hydroxymethyl)pyridinium chloride；2-methanolpyridine hydrochloride；pyridin-1-ium-2-ylmethanol;chloride
• CAS: 6329-89-1
• 化学式: C₆H₈NO*Cl
• mdl: MFCD00006349
• 分子量: 145.589
• InChiKey: GSOOLIFIQJUSFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  33.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-吡啶甲醇盐酸盐 在 氢溴酸 、 potassium carbonate 作用下， 反应 20.0h， 生成 N-methyl-N¹-<2-(2-pyridinylmethylthio)ethyl>urea
  参考文献：
  名称：

  El-Badry; Knaus, European Journal of Medicinal Chemistry, 1985, vol. 20, # 5, p. 403 - 407

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-吡啶甲醇 在 2-吡啶甲醇盐酸盐 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 为溶剂， 以55%的产率得到2-氯甲基吡啶
  参考文献：
  名称：

  Alpegiani, Marco; Bedeschi, Angelo; Perrone, Ettore, Gazzetta Chimica Italiana, 1985, vol. 115, # 7, p. 393 - 394

  摘要：

  DOI：

文献信息

• NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS.
  申请人：GALAPAGOS NV

  公开号：US20130165437A1

  公开（公告）日：2013-06-27

  A compound according to Formula Ia: wherein L 1 , G, and R 1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据以下公式Ia的化合物： 其中L1、G和R1如本文所述。 本发明涉及根据公式I的新化合物，这些化合物对抗GPR84，G蛋白偶联受体，该受体参与炎症病症，以及这些新化合物的生产方法，包含这些化合物的药物组合物，以及通过给予本发明的化合物来预防和/或治疗炎症病症（例如炎症性肠病（IBD）、类风湿关节炎、血管炎、肺部疾病（例如慢性阻塞性肺病（COPD）和肺间质疾病（例如特发性肺纤维化（IPF）））、神经炎症病症、传染病、自身免疫疾病、内分泌和/或代谢疾病，以及/或通过给予本发明的化合物导致免疫细胞功能受损的疾病。
• Substituent effect of substrates on cucurbit[8]uril-catalytic oxidation of aryl alcohols
  作者：Hang Cong、Zhao-Jie Li、Yong-Huan Wang、Zhu Tao、Takehiko Yamato、Sai-Feng Xue、Gang Wei

  DOI：10.1016/j.molcata.2013.03.010

  日期：2013.8

  Based on the formation of the ternary host–guest inclusion complex between veratryl alcohol, o-iodoxybenzoic acid (IBX) and cucurbit[8]uril (Q[8]), the effect of substrate substituents on the IBX oxidation of aryl alcohols to the corresponding aldehyde subject to supramolecular catalysis by Q[8] in aqueous solvent is described. Aryl alcohols with different substituent effect on electron, for example, 2

  基于藜芦醇，邻碘氧基苯甲酸（IBX）和葫芦[8]尿素（Q [8]）之间的三元主客体包合配合物的形成，底物取代基对IBX氧化芳基醇至芳烃的影响描述了在水性溶剂中通过Q [8]超分子催化的相应醛。对电子具有不同取代基作用的芳基醇，例如2,3,4-甲氧基苄基醇和2,3,4-吡啶甲醇甲醇盐酸盐，已经过IBX流程在室温下，在不存在和存在Q [8]的情况下氧化。Q [8]的催化能力表明，取代基对芳醇的α-碳的电子效应对于Q [8]的催化氧化至关重要，并从机理上建议Q [8]的超分子催化作用是：对醇的贡献主要是对取代基的负诱导作用。
• Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
  申请人：GALAPAGOS NV

  公开号：US11220499B2

  公开（公告）日：2022-01-11

  A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  符合式 Ia 的化合物： 其中 L1、G 和 R1 如本文所述。 本发明涉及根据式 I 可拮抗参与炎症的 G 蛋白偶联受体 GPR84 的新型化合物、生产这些新型化合物的方法、包含这些化合物的药物组合物以及预防和/或治疗炎症（例如炎症性肠病 (IBD)、类风湿性关节炎、血管炎、肺部疾病（如慢性阻塞性肺病 (COPD) 和肺间质疾病（如特发性肺纤维化 (IPF)））的方法。如慢性阻塞性肺病（COPD）和肺间质疾病（如特发性肺纤维化（IPF）））、神经炎症、感染性疾病、自身免疫性疾病、内分泌和/或代谢性疾病和/或涉及免疫细胞功能损害的疾病。
• Cobalt(II) complexes of 2-methanol-, 2,6-dimethanol- and 2-ethanolpyridines: syntheses, spectroscopic, thermal and structural characterizations of [Co2(μ-Cl)2(mpy)4]Cl2·2H2O, [Co(dmpy)2]Cl2 and [Co(Cl)4](Hpyet)2 (mpy=2-methanolpyridine; dmpy=2,6-dimethanolpyridine and Hpyet=2-ethanolpyridinium)
  作者：Veysel T Yilmaz、Sevim Hamamci、Carsten Thöne

  DOI：10.1016/j.poly.2003.12.007

  日期：2004.3

  Cobalt(II) complexes of 2-methanol-, 2,6-dimethanol- and 2-ethanolpyridines have been prepared by the reaction of the corresponding protonated substituted pyridines with [Co(sac)(2)(H2O)(4)](.)2H(2)O, where sac is saccharinate, and characterised by elemental analyses, IR, UV-Vis, magnetic measurements and single crystal X-ray diffraction. The corresponding 2-methanolpyridine (mpy) complex [Co-2(mu-Cl)(2)(mpy)(4)]Cl(2)(.)2H(2)O is dimeric with chloro bridges and each cobalt(II) ion has an octahedral coordination with two chloro and two bidentate (N, O) ligands. In the 2,6-dimethanolpyridine (dmpy) complex [Co(dmpy)(2)]Cl-2, dmpy exhibits a tripodal chelating coordination mode through the N and two hydroxyl O atoms forming a CoN2O4 chromophore. The protonated 2-ethanolpyridinium cation Hpyet serves as a non-coordinating, but hydrogen bonded counter ion in [Co(Cl)(4)](Hpyet)(2). Based on the molecular structures, the electronic, IR spectra and thermal behavior of the complexes are discussed. 16 (C) 2003 Elsevier Ltd. All rights reserved.
• NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Galapagos NV

  公开号：EP2794604A1

  公开（公告）日：2014-10-29